Coherent, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Plans for a secondary offering of 3 mil. shares of common stock are outlined in a registration statement filed with the SEC. Santa Clara, California-based Coherent, which gained FDA approval in April for its Opal Photoactivator laser for use in photodynamic therapy with QLT PhotoTherapeutics' Visudyne (verteporfin for injection) to treat "wet" age-related macular degeneration (1"The Gray Sheet" April 17, In Brief), says it plans to use the proceeds "for acquisitions of and investments in businesses, technologies and products, continued development of new technologies and general corporate purposes." Underwriters UBS Warburg, CIBC World Markets, U.S. Bancorp Piper Jaffray and BlueStone Capital Partners will have an option for up to 450,000 overallotment shares